AR080785A1 - Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros. - Google Patents
Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros.Info
- Publication number
- AR080785A1 AR080785A1 ARP110100945A ARP110100945A AR080785A1 AR 080785 A1 AR080785 A1 AR 080785A1 AR P110100945 A ARP110100945 A AR P110100945A AR P110100945 A ARP110100945 A AR P110100945A AR 080785 A1 AR080785 A1 AR 080785A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- heteroaryl
- optionally substituted
- alkoxy
- heterocyclyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Reivindicacion 1: Un compuesto de la formula (1) en la que R1 es fenilo o tienilo, dichos fenilo y tienilo están opcionalmente sustituidos de 1 a 3 veces por sustituyentes elegidos con independencia entre el grupo formado por hidroxilo, halogeno, alquilo inferior, alcoxi inferior, haloalquilo inferior, haloalcoxi inferior, (alcoxi inferior)-alquilo inferior, -OC(O)-alquilo inferior, -OCH2C(O)-alcoxi inferior y fenilo; R2 es un heteroarilo monocíclico de 5 o 6 eslabones que tiene de 1 a 3 heteroátomos elegidos con independencia entre N y O, dicho heteroarilo está opcionalmente sustituido de 1 a 3 veces por sustituyentes elegidos con independencia entre el grupo formado el resto de formula (2), halogeno, hidroxilo, nitro, alquilo inferior, alquenilo inferior, alcoxi inferior, alcoxi inferior-C(O)-, hidroxialquilo inferior, haloalquilo inferior, (alcoxi inferior)-alquilo inferior, (alquilo inferior)-C(O)-, cicloalquilo, heterociclilo, arilo, heteroarilo y amino opcionalmente sustituido por heteroarilo, en el que dos sustituyentes de R2, junto con dicho heteroarilo al que están unidos, pueden formar un anillo bicíclico de 9 o 10 eslabones; R3 y R3' son con independencia hidrogeno, alquilo inferior, hidroxialquilo inferior, cianoalquilo inferior, haloalquilo inferior, (alcoxi inferior)-alquilo inferior, cicloalquilo, cianocicloalquilo, heterociclilo o arilo, dicho alquilo inferior está opcionalmente sustituido por haloalcoxi inferior, cicloalquilo, arilo o heteroarilo, dicho heteroarilo está opcionalmente sustituido de 1 a 3 veces por sustituyentes elegidos con independencia entre el grupo formado por halogeno, nitro, ciano, alquilo inferior, haloalquilo inferior, alcoxi inferior y cicloalquilo y dicho heterociclilo está opcionalmente sustituido por alquilo inferior, o R3 y R3', junto con el átomo de nitrogeno al que están unidos, forman un heterociclilo, 2,5-dihidro-1H-pirrol, 2-metil-2,4,5,6-tetrahidropirrolo[3,4-c]pirazol o 2-oxa-6-aza-espiro[3.3]heptano, dicho heterociclilo está opcionalmente sustituido de 1 a 3 veces por halogeno, hidroxilo, oxo, alquilo inferior o heteroarilo; R8 es hidrogeno, alquilo inferior, alcoxi inferior o (alcoxi inferior)-alquilo inferior; o sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10158011 | 2010-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR080785A1 true AR080785A1 (es) | 2012-05-09 |
Family
ID=43989818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110100945A AR080785A1 (es) | 2010-03-26 | 2011-03-23 | Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8410117B2 (es) |
| EP (1) | EP2552918B1 (es) |
| JP (1) | JP5764196B2 (es) |
| KR (1) | KR20130073876A (es) |
| CN (1) | CN102791714B (es) |
| AR (1) | AR080785A1 (es) |
| AU (1) | AU2011231668A1 (es) |
| BR (1) | BR112012024199A2 (es) |
| CA (1) | CA2786213A1 (es) |
| CL (1) | CL2012002497A1 (es) |
| CR (1) | CR20120443A (es) |
| EC (1) | ECSP12012174A (es) |
| ES (1) | ES2478448T3 (es) |
| IL (1) | IL220932A0 (es) |
| MA (1) | MA34069B1 (es) |
| MX (1) | MX2012010880A (es) |
| NZ (1) | NZ600927A (es) |
| PE (1) | PE20130382A1 (es) |
| PH (1) | PH12012501772A1 (es) |
| RU (1) | RU2562066C2 (es) |
| SG (1) | SG183824A1 (es) |
| TW (1) | TWI478924B (es) |
| UA (1) | UA108640C2 (es) |
| WO (1) | WO2011117264A1 (es) |
| ZA (1) | ZA201206257B (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140009372A (ko) | 2011-02-18 | 2014-01-22 | 알러간, 인코포레이티드 | 포스포다이에스테라제 10(pde10a)의 억제제로서의 치환된 6,7-다이알콕시-3-아이소퀴놀리놀 유도체 |
| WO2013059589A1 (en) * | 2011-10-20 | 2013-04-25 | Sirtris Pharmaceuticals, Inc. | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
| EP2768509B1 (en) | 2011-10-20 | 2017-03-22 | Glaxosmithkline LLC | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
| EP2768833A4 (en) * | 2011-10-20 | 2015-04-15 | Sirtris Pharmaceuticals Inc | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS MODULATORS OF SIRTUINS |
| BR112015002779A2 (pt) * | 2012-08-17 | 2019-10-15 | Hoffmann La Roche | processo para a preparação de derivados de ácido carboxílico de pirazol |
| WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| CN104768554B (zh) * | 2012-11-07 | 2018-04-17 | 霍夫曼-拉罗奇有限公司 | 三唑并化合物 |
| CN102964308B (zh) * | 2012-11-30 | 2015-03-18 | 中国药科大学 | 新型嘧啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途 |
| EP2963037B1 (en) | 2013-02-27 | 2019-03-27 | Mochida Pharmaceutical Co., Ltd. | Novel pyrazole derivative |
| ES2629389T3 (es) * | 2013-05-23 | 2017-08-09 | H. Hoffnabb-La Roche Ag | 2-fenilimidazo[1,2-a]pirimidinas como agentes de obtención de imágenes |
| WO2015006689A1 (en) | 2013-07-12 | 2015-01-15 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression |
| JP6182668B2 (ja) * | 2013-09-26 | 2017-08-16 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 画像化ツールとしてのイミダゾ［１，２−ａ］ピリジン−７−アミン |
| US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
| PL408251A1 (pl) | 2014-05-19 | 2015-11-23 | Celon Pharma Spółka Z Ograniczoną Odpowiedzialnością | Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A |
| CA2956262A1 (en) * | 2014-07-30 | 2016-02-04 | Mochida Pharmaceutical Co., Ltd. | Pyrazole derivative manufacturing method |
| KR20180082432A (ko) * | 2015-09-29 | 2018-07-18 | 온코세라피 사이언스 가부시키가이샤 | 비시클릭 화합물 및 suv39h2 를 저해하기 위한 이의 용도 |
| US20170107216A1 (en) | 2015-10-19 | 2017-04-20 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| AU2016358100B2 (en) | 2015-11-19 | 2021-05-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| TW201726623A (zh) | 2015-12-17 | 2017-08-01 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
| TWI850624B (zh) | 2015-12-22 | 2024-08-01 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
| TW201808950A (zh) | 2016-05-06 | 2018-03-16 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
| US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| DK3472167T3 (da) | 2016-06-20 | 2022-09-05 | Incyte Corp | Heterocykliske forbindelser som immunomodulatorer |
| EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| EP3504198B1 (en) | 2016-08-29 | 2023-01-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2929193T3 (es) | 2016-12-22 | 2022-11-25 | Incyte Corp | Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de la internalización de PD-L1 |
| ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
| EP3558973B1 (en) | 2016-12-22 | 2021-09-15 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| EP3558963B1 (en) | 2016-12-22 | 2022-03-23 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| IL295660A (en) | 2016-12-22 | 2022-10-01 | Incyte Corp | Benzooxazole derivatives as immunomodulators |
| TWI674260B (zh) | 2017-02-01 | 2019-10-11 | 德商菲尼克斯製藥股份有限公司 | 芳基烴受體(AhR)調節劑化合物 |
| TWI752155B (zh) | 2017-02-01 | 2022-01-11 | 德商菲尼克斯製藥股份有限公司 | 芳香烴受體(AhR)調節劑化合物 |
| RS64055B1 (sr) | 2018-03-30 | 2023-04-28 | Incyte Corp | Heterociklična jedinjenja kao imunomodulatori |
| EP4219492B1 (en) | 2018-05-11 | 2024-11-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2020094591A1 (en) | 2018-11-06 | 2020-05-14 | H. Lundbeck A/S | Pde10a inhibitors for treating negative symptoms and cognitive impairments in a patient suffering from schizophrenia |
| BR112020013697A2 (pt) | 2018-11-06 | 2020-12-01 | H. Lundbeck A/S | compostos para tratamento de sintomas negativos e comprometimentos cognitivos |
| JP7665593B2 (ja) | 2019-08-09 | 2025-04-21 | インサイト・コーポレイション | Ｐｄ－１／ｐｄ－ｌ１阻害剤の塩 |
| EP4037773A1 (en) | 2019-09-30 | 2022-08-10 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
| CN114929230B (zh) * | 2019-10-21 | 2024-11-29 | 爱思开生物制药株式会社 | 咪唑并嘧啶或咪唑并三嗪化合物用于预防、减轻或治疗认知障碍或者用于改善认知功能的用途 |
| BR112022009031A2 (pt) | 2019-11-11 | 2022-10-11 | Incyte Corp | Sais e formas cristalinas de um inibidor de pd-1/pd-l1 |
| CN115427050B (zh) * | 2020-02-07 | 2025-02-14 | 南佛罗里达大学 | 对tau蛋白病中的β-抑制蛋白寡聚化的抑制 |
| US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
| EP4240739A1 (en) | 2020-11-06 | 2023-09-13 | Incyte Corporation | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof |
| WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
| CN115572282B (zh) * | 2021-07-05 | 2024-07-09 | 华东理工大学 | 含芳杂环结构的吡唑酰胺类化合物及其制备方法和应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES493459A0 (es) | 1980-07-17 | 1981-07-01 | Consejo Superior Investigacion | Procedimiento para la preparacion de 3(6 5)-formilpira- zol-4-carboxilatos de alquilo |
| MXPA01007019A (es) * | 1999-11-10 | 2002-09-18 | Johnson & Johnson | 2-aril-3-(heteroaril)-imidazo[1,2-a]pirimidinas, sustituidas y composiciones farmaceuticas relacionados y metodos. |
| JP2004501109A (ja) | 2000-05-24 | 2004-01-15 | メルク シャープ エンド ドーム リミテッド | Ｇａｂａ受容体に対するリガンドとしての３−フェニル−イミダゾ−ピリミジン誘導体 |
| US6596731B2 (en) | 2001-03-27 | 2003-07-22 | Hoffmann-La Roche Inc. | Substituted imidazo[1,2-A] pyridine derivatives |
| FR2825705B1 (fr) | 2001-06-08 | 2005-05-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens |
| CA2534292A1 (en) * | 2003-07-30 | 2005-02-17 | Laboratorios S.A.L.V.A.T., S.A. | Substituted imidazopyrimidines for the prevention and treatment of cancer |
| WO2005012485A2 (en) | 2003-07-31 | 2005-02-10 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
| WO2007034282A2 (en) * | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists |
| AU2007207053B2 (en) * | 2006-01-17 | 2012-05-24 | F. Hoffmann-La Roche Ag | Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine useful for the treatment of Alzheimer's disease via GABA receptors |
| US7951824B2 (en) | 2006-02-17 | 2011-05-31 | Hoffman-La Roche Inc. | 4-aryl-pyridine-2-carboxyamide derivatives |
| KR101532256B1 (ko) * | 2006-11-22 | 2015-06-29 | 인사이트 코포레이션 | 키나제 억제제로서의 이미다조트리아진 및 이미다조피리미딘 |
| EP1964841A1 (en) * | 2007-02-28 | 2008-09-03 | sanofi-aventis | Imidazo[1,2-a]azine and their use as pharmaceuticals |
| DE102007048716A1 (de) * | 2007-10-11 | 2009-04-23 | Merck Patent Gmbh | Imidazo[1,2-a]pyrimidinderivate |
| FR2926556B1 (fr) * | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique |
| TWI501965B (zh) * | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
-
2011
- 2011-03-17 US US13/049,941 patent/US8410117B2/en not_active Expired - Fee Related
- 2011-03-22 TW TW100109761A patent/TWI478924B/zh active
- 2011-03-23 JP JP2013501753A patent/JP5764196B2/ja not_active Expired - Fee Related
- 2011-03-23 UA UAA201211970A patent/UA108640C2/uk unknown
- 2011-03-23 MA MA35218A patent/MA34069B1/fr unknown
- 2011-03-23 BR BR112012024199A patent/BR112012024199A2/pt active Search and Examination
- 2011-03-23 ES ES11711068.4T patent/ES2478448T3/es active Active
- 2011-03-23 MX MX2012010880A patent/MX2012010880A/es active IP Right Grant
- 2011-03-23 WO PCT/EP2011/054385 patent/WO2011117264A1/en not_active Ceased
- 2011-03-23 AR ARP110100945A patent/AR080785A1/es unknown
- 2011-03-23 RU RU2012143794/04A patent/RU2562066C2/ru not_active IP Right Cessation
- 2011-03-23 NZ NZ600927A patent/NZ600927A/xx not_active IP Right Cessation
- 2011-03-23 AU AU2011231668A patent/AU2011231668A1/en not_active Abandoned
- 2011-03-23 PH PH1/2012/501772A patent/PH12012501772A1/en unknown
- 2011-03-23 SG SG2012064044A patent/SG183824A1/en unknown
- 2011-03-23 EP EP11711068.4A patent/EP2552918B1/en not_active Not-in-force
- 2011-03-23 KR KR1020127027825A patent/KR20130073876A/ko not_active Ceased
- 2011-03-23 CA CA2786213A patent/CA2786213A1/en not_active Abandoned
- 2011-03-23 CN CN201180013745.6A patent/CN102791714B/zh not_active Expired - Fee Related
- 2011-03-23 PE PE2012001636A patent/PE20130382A1/es not_active Application Discontinuation
-
2012
- 2012-07-12 IL IL220932A patent/IL220932A0/en unknown
- 2012-08-20 ZA ZA2012/06257A patent/ZA201206257B/en unknown
- 2012-08-24 CR CR20120443A patent/CR20120443A/es unknown
- 2012-09-10 CL CL2012002497A patent/CL2012002497A1/es unknown
- 2012-09-24 EC ECSP12012174 patent/ECSP12012174A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA34069B1 (fr) | 2013-03-05 |
| SG183824A1 (en) | 2012-10-30 |
| TW201136937A (en) | 2011-11-01 |
| ZA201206257B (en) | 2013-05-29 |
| PH12012501772A1 (en) | 2017-07-26 |
| JP5764196B2 (ja) | 2015-08-12 |
| UA108640C2 (uk) | 2015-05-25 |
| RU2562066C2 (ru) | 2015-09-10 |
| CR20120443A (es) | 2012-10-11 |
| ECSP12012174A (es) | 2012-10-30 |
| CN102791714A (zh) | 2012-11-21 |
| MX2012010880A (es) | 2012-10-15 |
| WO2011117264A1 (en) | 2011-09-29 |
| CA2786213A1 (en) | 2011-09-29 |
| CN102791714B (zh) | 2015-03-25 |
| US20110237564A1 (en) | 2011-09-29 |
| KR20130073876A (ko) | 2013-07-03 |
| AU2011231668A1 (en) | 2012-07-19 |
| EP2552918B1 (en) | 2014-06-11 |
| EP2552918A1 (en) | 2013-02-06 |
| TWI478924B (zh) | 2015-04-01 |
| HK1173440A1 (en) | 2013-05-16 |
| IL220932A0 (en) | 2012-09-24 |
| NZ600927A (en) | 2013-08-30 |
| US8410117B2 (en) | 2013-04-02 |
| RU2012143794A (ru) | 2014-05-10 |
| ES2478448T3 (es) | 2014-07-22 |
| BR112012024199A2 (pt) | 2016-07-05 |
| JP2013523673A (ja) | 2013-06-17 |
| CL2012002497A1 (es) | 2013-03-22 |
| PE20130382A1 (es) | 2013-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR080785A1 (es) | Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros. | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| PE20130376A1 (es) | [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| ES2600636T3 (es) | Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2 | |
| PE20130306A1 (es) | Morfolinopirimidinas y su uso en terapia | |
| PE20142456A1 (es) | COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks | |
| PE20121815A1 (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6 | |
| MX2018003215A (es) | Derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftirid ina novedosos como inhibidores de lrrk2. | |
| PE20091833A1 (es) | Derivados heterociclicos espiro biciclicos o heterociclicos biciclicos, puenteados, de pirazolo [1,5-a]pirimidinas como inhibidores de quinasas raf y metodos para su preparacion | |
| PE20140927A1 (es) | Compuestos heterociclicos como inhibidores de cinasas | |
| DOP2014000303A (es) | 7H-PIRROLO[2,3-d] PIRIMIDINAS 4-(AMINO-SUBSTITUIDAS) NOVEDOSAS COMO INHIBIDORES DE LRRK2 | |
| PE20120172A1 (es) | Compuestos heterociclicos fusionados que contiene nitrogeno como inhibidores de la produccion de beta-amiloide | |
| PE20130012A1 (es) | Derivados de pirazol como inhibidores de jak | |
| PE20190653A1 (es) | Nuevos derivados de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR085316A1 (es) | Derivados de pirrolo[2,3-b]piridina, utiles para la modulacion de quinasas | |
| DOP2014000055A (es) | Derivados de pirrolopirimidina y purina | |
| CO6410299A2 (es) | Derivados de triazolo [4,3-b] pridazina y sus usos para el cáncer de próstata | |
| AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
| ECSP11011470A (es) | Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades | |
| PE20142164A1 (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| UY33458A (es) | Derivados de metoxifenilo heterocíclicamente sustituidos con un grupo oxo, procedimientos para su preparación y uso de los mismos como medicamentos | |
| PE20120534A1 (es) | PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt | |
| ES2603931T3 (es) | Compuestos de triazolo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |